Cardiac PET

Cardiac positron emission tomography (PET) is a nuclear imaging modality that can show heart cell metabolism that reveals areas of ischemia or infarct where this low or no blood flow due to coronary artery disease and myocardial infarction. PET can help determine in if areas of the heart effected by a heart attack can be reversed through revascularization. PET can also offer additional information on the patient's condition with myocardial flow reserve (MFR) information. Cardiac PET uses a rubidium (Rb-82) radiotracer injection, which only has a half life of 75 seconds, which greatly speeds scan times compared to traditional cardiac SPECT imaging.

The new cardiac PET radiotracer flurpiridaz F-18 is posed to be a major game changer and will likely lead to increased adoption of cardiac PET.

FDA approves GE HealthCare's flurpiridaz F-18 PET radiotracer for CAD

The newly approved radiotracer is seen as a major step forward for nuclear imaging technology. Specialists have been looking forward to its arrival on the market for quite some time.

Erin R. Stevens, CNMT, NCT, director of nuclear medicine at Oregon Heart Center, said training physicians for what is needed in cardiac PET documentation is key for preventing issues with prior authorizations. ASNC photo

Good documentation is the key to cardiac PET prior authorizations

Knowing what, exactly, is needed in cardiac PET documentation is one of the best ways to limit prior authorization issues.

Cardiac PET on the rise among U.S. cardiologists

SPECT is still the most common modality used to evaluate CAD patients, but cardiac PET is gaining more and more momentum.

Numerous advances in cardiac nuclear imaging led American Society of Nuclear Cardiology (ASNC) President-elect Panithaya Chareonthaitawee, MD, to predict "We are on the edge of a new journey in nuclear cardiology, and the opportunities before us are just as vast as they are exciting and promising."

ASNC president-elect predicts unprecedented innovation in nuclear cardiology

"We are on the edge of a new journey in nuclear cardiology," explained ASNC President-elect Panithaya Chareonthaitawee, MD.

 

doctor examines patient data on their tablet

FDA sees potential in new PET imaging agent for cardiac amyloidosis

Early evidence suggests a new PET imaging agent from California-based Attralus can help evaluate all varieties of systemic cardiac amyloidosis. It has now been granted the FDA's breakthrough therapy designation. 

Video interview with Tim Bateman, MD, co-director, cardiovascular radiologic imaging program, Saint Luke's Mid America Heart Institute and an American Society of Nuclear Cardiology (ASNC) past-president, explaining the role of SPECT into the future as PET becomes more popular. A new look at PET vs SPECT.

SPECT still has an important role to play in nuclear cardiology

"I see, at least for the next decade, this being a SPECT and PET world, not one or the other," explained Tim Bateman, MD.

Thumbnail

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Video interview with ASNC President Lawrence Phillips, MD, NYU, who is encouraging the modernization of nuclear cardiology labs and expansion into new diagnostic areas.

ASNC president pushes to modernize nuclear cardiology, expand the specialty's reach

ASNC President Lawrence Phillips, MD, wants to see nuclear cardiologists modernize their labs and embrace new strategies for the evaluation of amyloidosis, sarcoidosis and inflammation.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Trimed Popup
Trimed Popup